In the wake of the Theranos controversy, thousands of consumers were left without a reliable platform for at-home blood testing for chronic illnesses such as Celiac Disease and Rheumatoid Arthritis and other autoimmune diseases.
That is why one company decided that they not only needed to make a platform that was accurate but that one where consumers can feel more empowered. imaware, the at-home testing platform for chronic illness and disease, designed by healthcare company Microdrop, has released a study utilizing its platform has been peer-reviewed by one of the world’s top clinical chemistry journals, Clinical Chemistry and Laboratory Medicine (CCLM).
imaware Background
The company is the first at-home blood-testing platform to validate and share its data with consumers and medical professionals. imaware offers at-home tests for Celiac Disease and Rheumatoid Arthritis, with cardiovascular health, liver disease and prostate health tests launching later this year. The company’s published results in CCLM can be found here.
This at-home blood testing platform was developed alongside doctors that debunked Theranos’ junk science and the platform leverage proven methods in research and laboratory settings.
The company uses a proven microarray testing platform commonly used in research and laboratory settings that are designed for sample sizes of just 50-100 microLiters of blood. By pricking their finger, people collect the blood at home in a small vial and send it to imaware for testing. Testing is conducted on imaware platforms at CLIA-certified partner laboratories located in Missouri and Texas. The results are then shared in a secure and private online portal with additional resources and access to local medical professionals.
In less than three months the company has processed thousands of patient results on the platform. Medical advisors include Dr. Diamandis who was first to debunk Theranos’ science and Dr. Spitz who was appointed by President Obama to the National Cancer Advisory Board.
“The imaware at-home screening test for celiac disease is the first to combine four biomarkers into one test and provide results within several days that patients can then share with their doctors,” said Dr. Guandalini, imaware medical advisor and Professor Emeritus and Founder, University of Chicago Celiac Disease Center. “This should help reduce the significant number of undiagnosed patients with celiac disease. The validity of the test is supported by specific data that have been recently published in a leading clinical chemistry journal after successfully undergoing a peer review process.”
Pricing and Availability
Available online at imaware.health for $99, all tests use a small amount of blood obtained through a finger prick and collected in a vial. People mail in the sample and within five days receive their confidential test results via a secure online portal. Multiple biomarkers commonly associated with chronic illnesses such as Celiac Disease and Rheumatoid Arthritis are measured. The imaware™ tests are currently available in the United States.
